TrialColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2022

A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis.

Amy L Lightner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.